Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.73 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 11/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.71 |
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460730 | 0.89 | CXCR2 (0.73) | CXCR2CXCR1MEN1KMT2AMAPT | |
| SCHEMBL32689896 | 0.86 | CA12 (0.71) | CXCR2CXCR1MEN1KMT2AMAPT | |
| SCHEMBL4548109 | 0.86 | CA12 (0.71) | CXCR2CXCR1MEN1KMT2AMAPT | |
| SCHEMBL5595042 | 0.84 | CXCR2 (1.00) | CXCR2CXCR1MEN1KMT2AMAPT | |
| SCHEMBL15133011 | 0.84 | CA12 (0.69) | CXCR2CXCR1MEN1KMT2AMAPT | |
| SCHEMBL673216 | 0.83 | CA2 (1.00) | CXCR2CXCR1MEN1KMT2AMAPT | |
| Diphenylurea SCHEMBL27302793 | 0.82 | MEN1 (0.81) | CXCR2CXCR1MEN1KMT2AMAPT | |
| SCHEMBL402139 | 0.82 | MAPT (0.77) | MEN1KMT2AMAPTLMNAMAPK1 | |
| SCHEMBL5595180 | 0.82 | CXCR2 (1.00) | CXCR2CXCR1MEN1KMT2AMAPT | |
| SCHEMBL31222305 | 0.82 | CXCR2 (1.00) | CXCR2CXCR1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889678-B2 | Acyl guanidine derivatives modulating the hedgehog protein signaling pathway | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-11-18 | — | — | US | disclosed |
| US-8889678-B2 | Acyl guanidine derivatives modulating the hedgehog protein signaling pathway | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-11-18 | — | — | US | disclosed |
| EP-2456754-B1 | ACYL GUANIDINE DERIVATIVES MODULATING THE HEDGEHOG PROTEIN SIGNALING PATHWAY | UNIV STRASBOURG (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-20120196865-A1 | Acyl Guanidine Derivatives Modulating The Hedgehog Protein Signaling Pathway | UNIVERSITE DE STRASBOURG (FR) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196865-A1 | Acyl Guanidine Derivatives Modulating The Hedgehog Protein Signaling Pathway | UNIVERSITE DE STRASBOURG (FR) | 2012-08-02 | — | — | US | disclosed |
| WO-2011010013-A1 | ACYL GUANIDINE DERIVATIVES MODULATING THE HEDGEHOG PROTEIN SIGNALING PATHWAY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196865-A1 | Acyl Guanidine Derivatives Modulating The Hedgehog Protein Signaling Pathway | SHH, GLI1, SMO | CXCR2 2250/4885CXCR1 2850/4885MEN1 4544/4885 |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | CXCR2 125/4885CXCR1 290/4885MEN1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.